Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 36Carcinoma, Renal Cell 16Prostatic Neoplasms 10Neoplasm Metastasis 10Leukemia, Myeloid, Acute 9Carcinoma, Non-Small-Cell Lung 9Uveal Melanoma 8Myelodysplastic Syndromes 8Leukemia, Lymphocytic, Chronic, B-Cell 7Clear-cell metastatic renal cell carcinoma 7Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Multiple Myeloma 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Lymphoma, Follicular 4Histiocytoma, Malignant Fibrous 4Gastrointestinal Stromal Tumors 4Burkitt Lymphoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3

Interventions

Magnetic Resonance Spectroscopy 17Iodine-131 16lenvatinib 13trametinib 12Thyrotropin Alfa 11Sorafenib 11pembrolizumab 10dabrafenib 10Paclitaxel 9vandetanib 8Thyroxine 8Surgical Procedures, Operative 7Sunitinib 7selpercatinib 6cabozantinib 6Nivolumab 6Fluorodeoxyglucose F18 6Everolimus 6pazopanib 5Vemurafenib 5Thyroidectomy 5Specimen Handling 5Saline Solution 5Radiotherapy 5Radiofrequency Ablation 5Cyclophosphamide 5Cisplatin 5Biopsy 5apatinib 4anlotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Thyroid Neoplasms × CTLA-4 Antigen × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03914300 2026-06-01

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡